- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Biosergen AB: Nasdaq approves Biosergen's application for delisting from First North Growth Market conditional upon the Swedish Companies Registration Office granting permission to execute the merger with Flerie | 198 | GlobeNewswire (Europe) | Biosergen AB ("Biosergen" or the "Company") applied on 15 September 2026 for delisting of the Company's shares from Nasdaq First North Growth Market, in connection with the contemplated merger between... ► Artikel lesen | |
| Di | Biosergen AB: Biosergen applies for delisting of the company's shares from Nasdaq First North Growth Market conditional upon completion of the merger with Flerie | 139 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB ("Biosergen" or the "Company") has today, on 15 September 2026, in connection with the contemplated merger between Biosergen and Flerie AB (publ) ("Flerie") (the... ► Artikel lesen | |
| FLERIE Aktie jetzt für 0€ handeln | |||||
| 06.08. | Flerie AB: Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 6 August 2026 at 11:00 CEST | 159 | GlobeNewswire (Europe) | The extraordinary general meeting of Flerie AB (publ) reg. no. 559067-6820 ("Flerie" or the "Company") has been held on 6 August 2026 at 11:00 CEST at which the following resolutions were made.
Resolution... ► Artikel lesen | |
| 30.07. | Flerie AB: Biotech-Investments mit deutlichem NAV-Discount | 447 | investresearch.net | Flerie AB ist eine schwedische Beteiligungsgesellschaft, die sich auf den Biotech- und Healthcare-Sektor spezialisiert hat. Für Investoren, die den anspruchsvollen und risikoreichen Bereich der Biotechnologie... ► Artikel lesen | |
| 16.07. | BIOSERGEN AB: Flerie publishes merger document | 8 | Cision News | ||
| 09.07. | Flerie AB: Flerie AB (publ) Interim Report January - June 2026 | 287 | GlobeNewswire (Europe) | The period in brief• Net asset value was SEK 3,394 million (4,121) and net asset value per share was SEK 39.14 (52.78 on 30 June 2025). Change in net asset value per share in the quarter was -2.9 per... ► Artikel lesen | |
| 26.06. | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | 1.155 | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| 26.06. | Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | 380 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 26.06. | Flerie AB: Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm | 454 | GlobeNewswire (Europe) | Today, on 26 June 2026, Flerie AB (publ) ("Flerie") and Biosergen AB ("Biosergen") (together the "Companies") jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen... ► Artikel lesen | |
| 26.06. | Flerie AB: Flerie portfolio company Bonsai Biotherapeutics receives full approval of clinical trial application for TOL2 in myasthenia gravis | 414 | GlobeNewswire (Europe) | Flerie AB's portfolio company Bonsai Biotherapeutics has received full approval of its clinical trial application (CTA) for the drug candidate TOL2 for the treatment of AChR antibody-positive generalised... ► Artikel lesen | |
| 15.06. | Flerie AB: Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST | 187 | GlobeNewswire (Europe) | The extraordinary general meeting of Flerie AB (publ), reg. no. 559067-6820 ("Flerie" or the "Company") has been held on 15 June 2026 at 10:00 CEST at which the following main resolutions were made.
Resolution... ► Artikel lesen | |
| 14.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2026 | 801 | Xetra Newsboard | Das Instrument MD9 JP3879400004 MANDOM CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 14.05.2026 und ex Kapitalmassnahme am 15.05.2026 The instrument MD9 JP3879400004 MANDOM CORP. EQUITY is traded... ► Artikel lesen | |
| 11.05. | Flerie AB: Flerie's majority owner waives share allocation - other owners' stake in the company increases by approximately 15.5 per cent | 280 | GlobeNewswire (Europe) | In connection with the termination of Flerie's redemption scheme, the Annual General Meeting resolved to carry out a bonus issue. The company's largest shareholder, Thomas Eldered, has undertaken to... ► Artikel lesen | |
| 15.04. | Flerie AB: Flerie AB (publ) Interim Report January - March 2026 | 234 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,670 million (3,947) and net asset value per share was SEK 41.90 (50.56 at 31 March 2025). Change in net asset value per share in the quarter was -3.9 per... ► Artikel lesen | |
| 26.03. | Flerie AB: Bulletin from the Annual General Meeting of Flerie AB (publ) on 26 March 2026 | 483 | GlobeNewswire (Europe) | The Annual General Meeting of Flerie AB (publ) reg. no. 559067-6820 (the "Company") has been held on 26 March 2026 and in particular the following resolutions were made.
Adoption of the annual report... ► Artikel lesen | |
| 20.03. | Flerie AB: The merger between Flerie and Lipum has been completed | 411 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 12.03. | Lipum AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum | 338 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 11.02. | Flerie AB: Flerie's portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis | 312 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company Microbiotica has reported positive results from its Phase 1b first-in-human study of MB310 in patients with ulcerative colitis (UC). The positive data support Microbiotica's... ► Artikel lesen | |
| 02.02. | Flerie AB: Flerie's portfolio company Nanologica acquires Syntagon | 635 | GlobeNewswire (Europe) | Flerie AB (publ)'s portfolio company Nanologica has acquired Ardena Södertälje AB ('Syntagon'), a contract manufacturer with 45 employees. The acquisition strengthens Nanologica's production capacity... ► Artikel lesen | |
| 21.01. | Flerie AB: Flerie AB (publ) Year-end report 2025 | 253 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,377 million (4,198) and net asset value per share was SEK 43.60 (53.77 at 31 December 2024). Change in net asset value per share in the quarter was -13.8... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 129,85 | -1,22 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| SANOFI | 74,25 | +0,22 % | DEUTSCHE BANK RESEARCH stuft SANOFI auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi mit einem Kursziel von 95 Euro auf "Buy" belassen. Es sei der allgemeinen Aufmerksamkeit möglicherweise entgangenen... ► Artikel lesen | |
| EYEPOINT | 3,460 | +2,98 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| PHOTOCURE | 4,660 | 0,00 % | Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II | OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed... ► Artikel lesen | |
| BAYER | 48,090 | -1,94 % | Platzt der Knoten?: Bayer-Aktie vor dem wichtigsten Glyphosat-Termin der Unternehmensgeschichte? | © Foto: KI-generiert mit DALL-EVor fast 10 Jahren hat Bayer Monsanto übernommen. Damals hat wohl niemand in Leverkusen damit gerechnet, dass eine jahrelange Prozessflut damit verbunden ist. Biegt die... ► Artikel lesen | |
| IM CANNABIS CORP | 4,200 | -0,71 % | IM Cannabis Stock Surges 247% | ||
| NOVO NORDISK | 37,580 | -0,12 % | Novo Nordisk macht aus Wegovy immer mehr als ein Abnehm-Medikament - warum Big Pharma genau solche Plattformen sucht | ||
| DERMAPHARM | 38,900 | -0,26 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| KARDIGAN | 16,620 | -0,12 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 17,150 | 0,00 % | Generate Biomedicines auf der H.C. Wainwright Konferenz: Plattform-Strategie im Fokus | ||
| LB PHARMACEUTICALS | 42,370 | -0,24 % | LB Pharmaceuticals Appoints Susan Kozauer As CMO | ||
| ETON PHARMACEUTICALS | 55,48 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| APNIMED | 29,020 | +0,07 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| SCHOTT PHARMA | 23,450 | +1,08 % | JPMORGAN stuft Schott Pharma auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Bewertung von Schott Pharma beim Kursziel von 27,10 Euro mit "Overweight" aufgenommen. Der Spezialist für Aufbewahrung und Verabreichung injizierbarer... ► Artikel lesen | |
| ELI LILLY | 1.003,60 | +0,02 % | Umsatzschub zündet!: Rekordumsatz! Dieser Micro-Cap übertrifft nach acht Monaten bereits das gesamte Vorjahr |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLERIE AB finden Sie auf Wallstreet Online.